Expert Interview
Discussing Guardant Health’s recently approved blood test Shield as a primary screening option for colorectal cancer.
Ticker(s): GHInstitution: University of Florida
- Assistant Professor and Director of Inflammatory Bowel and Celiac Disease Program in the Division of Gastroenterology, Hepatology & Nutrition at University of Florida
- Treats 10-15 patients/year with celiac disease
- Clinical Interests in Crohn’s disease, ulcerative colitis, IBD, celiac disease, short bowel syndrome, and intestinal fistulas; Research focuses on improving the management of gastrointestinal diseases and exploring nutritional treatments for patient care.
Can non-invasive tests, like Cologuard or the newly FDA-approved Shield blood test, play a role in colorectal cancer screening, and how do they compare in terms of sensitivity and effectiveness compared to colonoscopies?
What percentage of your patients are resistant to colonoscopies, and could non-invasive options help bridge the gap for those unwilling to undergo traditional procedures?
How effective is Shield in detecting precancerous lesions and colorectal cancer compared to Cologuard, and what role might it play in your practice given its limitations?
Could Medicare coverage or guideline inclusion impact the adoption of Shield, and how does its potential cost compare to colonoscopy or Cologuard?
Added By: slingshot_insightsWhat factors influence a patient’s decision to opt for non-invasive tests like Shield, and how can physicians balance offering alternatives while ensuring optimal screening outcomes?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
